Evidence map›Paper›PMID 34532035›Full record

ReviewFood science & nutrition2021

The effects of ginseng on the metabolic syndrome: An updated review.

Tahereh Aminifard, Bibi Marjan Razavi, Hossein Hosseinzadeh

Open access · hybridAbstract readReview
In one paragraph

Review in Food science & nutrition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 41 citations in OpenAlex.

  1. Ashwagandha (Iranian journal of basic medical sciences · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Ginsenoside RbChinese herbal medicines · 2024
    Review
  9. Antioxidants (Basel, Switzerland) · 2024
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Food science & nutrition · 2023
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tahereh AminifardDepartment of Pharmacodynamics and Toxicology School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran.
Bibi Marjan RazaviDepartment of Pharmacodynamics and Toxicology School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran.
Hossein HosseinzadehDepartment of Pharmacodynamics and Toxicology School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran.ORCID https://orcid.org/0000-0002-3483-851X
Mashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic syndrome is a group of risk factors including high blood glucose, dyslipidemia, high blood pressure, and high body weight. It can increase the risk of diabetes and cardiovascular disorders, which are the important reasons for death around the world. Nowadays, there are numerous demands for herbal medicine because of less harmful effects and more useful effects in comparison with chemical options. Ginseng is one of the most famous herbs used as a drug for a variety of disorders in humans. The antihyperlipidemia, antihypertension, antihyperglycemic, and anti-obesity effects of ginseng and its active constituents such as ginsenosides have been shown in different studies. In this review article, the different in vitro, in vivo, and human studies concerning the effects of ginseng and its active constituents in metabolic syndrome have been summarized. According to these studies, ginseng can control metabolic syndrome and related diseases.

Indexed as

diabetesginsengherbal medicinehypertensionmetabolic syndromePanax ginseng

Identifiers

PMID34532035
PMCPMC8441279
OpenAlexW3185120019

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.